A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease.

Trial Profile

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2016

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms GEMINI-III
  • Sponsors Millennium
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Dec 2016 Post-hoc analysis results published in the Takeda Pharmaceutical Media Release.
    • 09 Dec 2016 According to a Takeda Pharmaceutical media release, an analysis based on pre-specified and post-hoc exploratory outcomes of GEMINI II and this study (GEMINI III) data was published in Inflammatory Bowel Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top